Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Anghileri

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Journal of Cellular and Molecular Medicine|October 14, 2025
Unique Genetic and Epigenetic Alterations in Glioblastoma Long-Term Survivors: Insights From Two Clinical CasesElena Anghileri, Evelina Miele, Sara Patrizi, et al.
Cancers|July 2, 2021
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)Marta Padovan, Marica Eoli, Alessia Pellerino, et al.
International Journal of Molecular Sciences|January 11, 2024
Development of A Radiomic Model for <i>MGMT</i> Promoter Methylation Detection in Glioblastoma Using Conventional MRIFabio M Doniselli, Riccardo Pascuzzo, Massimiliano Agrò, et al.
Bone|October 20, 2006
Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymusMauro Krampera, Silvia Marconi, Annalisa Pasini, et al.
Cancer Immunology, Immunotherapy : CII|November 3, 2020
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patientElena Anghileri, Natalia Di Ianni, Rosina Paterra, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 26, 2019
In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical settingValeria Cuccarini, Luigi Antelmi, Bianca Pollo, et al.
Quantitative Imaging in Medicine and Surgery|November 30, 2017
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitisCarla Schettino, Ferdinando Caranci, Giacomo Lus, et al.
Journal of Neurology|February 20, 2021
Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)Veronica Villani, Elena Anghileri, Luca Prosperini, et al.
The Oncologist|September 28, 2011
DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrenceFrancesca Menghi, Francesca N Orzan, Marica Eoli, et al.
Plos One|September 27, 2013
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecanLucia Cuppini, Angelica Calleri, Maria Grazia Bruzzone, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Journal of Cellular and Molecular Medicine|October 14, 2025
Unique Genetic and Epigenetic Alterations in Glioblastoma Long-Term Survivors: Insights From Two Clinical CasesElena Anghileri, Evelina Miele, Sara Patrizi, et al.
Cancers|July 2, 2021
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)Marta Padovan, Marica Eoli, Alessia Pellerino, et al.
International Journal of Molecular Sciences|January 11, 2024
Development of A Radiomic Model for <i>MGMT</i> Promoter Methylation Detection in Glioblastoma Using Conventional MRIFabio M Doniselli, Riccardo Pascuzzo, Massimiliano Agrò, et al.
Bone|October 20, 2006
Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymusMauro Krampera, Silvia Marconi, Annalisa Pasini, et al.
Cancer Immunology, Immunotherapy : CII|November 3, 2020
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patientElena Anghileri, Natalia Di Ianni, Rosina Paterra, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 26, 2019
In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical settingValeria Cuccarini, Luigi Antelmi, Bianca Pollo, et al.
Quantitative Imaging in Medicine and Surgery|November 30, 2017
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitisCarla Schettino, Ferdinando Caranci, Giacomo Lus, et al.
Journal of Neurology|February 20, 2021
Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)Veronica Villani, Elena Anghileri, Luca Prosperini, et al.
The Oncologist|September 28, 2011
DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrenceFrancesca Menghi, Francesca N Orzan, Marica Eoli, et al.
Plos One|September 27, 2013
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecanLucia Cuppini, Angelica Calleri, Maria Grazia Bruzzone, et al.
Pageof 5